Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Every cell in your body contains thymosin beta-4. It is one of the most abundant intracellular proteins — present in platelets that arrive first at wound sites, in inflammatory cells that coordinate repair, and in the stem cells that regenerate damaged tissue. TB-500, the synthetic fragment representing its active region, has become one of the most popular healing peptides in the biohacking and athletic recovery communities. The appeal: accelerate the same tissue-repair cascade your body already runs, just at higher concentrations.
What makes TB-500 distinct from BPC-157 in the healing-peptide space is that the parent molecule (full-length thymosin beta-4) actually has Phase II clinical trial data in humans — for cardiac repair after heart attacks, for diabetic wound healing, and for corneal damage. That partial clinical validation gives TB-500 a slightly stronger translational foundation than most non-approved peptides, even though the fragment itself has not been independently tested in controlled human trials.
What is TB-500?
TB-500 is a synthetic peptide consisting of the amino acid sequence of the active region (residues 17-23, or in some formulations a slightly larger fragment) of thymosin beta-4 (Tβ4). The full thymosin beta-4 protein is 43 amino acids long and is the primary G-actin (monomeric actin) sequestering protein inside mammalian cells. By binding actin monomers, Tβ4 regulates the availability of building blocks for the cytoskeleton — the internal scaffold that gives cells their shape, enables migration, and drives division.
The name "TB-500" originated from the veterinary/equine world, where synthetic thymosin beta-4 fragments were first used commercially for racehorse injury recovery. It is not an official pharmaceutical designation. In the clinical trial literature, the molecule studied is full-length thymosin beta-4 (sometimes designated RGN-352 or RGN-137 depending on formulation), not the abbreviated TB-500 fragment.
How does TB-500 work? Mechanism of action
The mechanism centers on actin dynamics and their downstream consequences for cellular behavior:
- G-actin sequestration: Thymosin beta-4 binds monomeric actin (G-actin), preventing premature polymerization into filaments (F-actin). This creates a reservoir of actin monomers available for rapid cytoskeletal reorganization when cells need to migrate, divide, or change shape
- Cell migration promotion: By modulating actin availability, TB-500 enhances the ability of keratinocytes, endothelial cells, and stem cells to migrate toward injury sites. Faster cell migration = faster wound coverage
- Angiogenesis: TB-500 promotes new blood vessel formation at injury sites — endothelial cell migration and tube formation are actin-dependent processes enhanced by thymosin beta-4
- Anti-inflammatory signaling: Tβ4 downregulates pro-inflammatory cytokines and chemokines in wound environments. It reduces NF-κB activation in some models, promoting a resolution-phase inflammatory profile that favors repair over chronic inflammation
- Cardiac protection: In ischemia-reperfusion models, Tβ4 activates the Akt (protein kinase B) survival pathway, promoting cardiomyocyte survival and reducing infarct size. This is the basis for cardiac clinical trials
- Hair follicle stem cell activation: Tβ4 promotes migration and differentiation of hair follicle stem cells — the basis for its investigated use in hair growth and the anecdotal reports of hair thickening
What does the research say?
Clinical trials (full-length thymosin beta-4)
RegeneRx Biopharmaceuticals conducted several clinical trials with full-length thymosin beta-4:
- Cardiac repair (RGN-352): Phase I/II trial in patients post-acute myocardial infarction. Intravenous Tβ4 was safe and well-tolerated. Preliminary efficacy signals showed trends toward improved cardiac function, but the trial was small and not powered for definitive efficacy conclusions
- Corneal wound healing (RGN-259): Phase II trials for neurotrophic keratopathy (chronic corneal wounds). Topical Tβ4 eye drops showed statistically significant improvement in corneal healing compared to placebo in some endpoints. This is the most encouraging clinical dataset
- Diabetic wound healing: Early-phase investigation of topical Tβ4 for chronic diabetic ulcers. Mixed results — some improvement in healing rates but not consistently reaching statistical significance across endpoints
- Epidermolysis bullosa: Topical Tβ4 investigated for wound healing in this genetic skin-fragility condition
Animal studies (TB-500 fragment and full Tβ4)
The animal literature is extensive, particularly in cardiac and wound-healing models. Key findings: Tβ4 reduces cardiac damage after experimental infarction (multiple groups have replicated this), accelerates dermal wound closure, promotes tendon healing in rat Achilles models, and reduces fibrosis in liver and cardiac tissue. The equine literature (racehorses) shows accelerated recovery from tendon and ligament injuries, which is where commercial TB-500 use originated.
| Study type | Form tested | Key findings |
|---|---|---|
| Phase II cardiac (human) | Full Tβ4 (RGN-352) IV | Safe; trends toward improved ejection fraction; underpowered for efficacy |
| Phase II corneal (human) | Full Tβ4 (RGN-259) topical | Significant corneal wound healing improvement vs. placebo |
| Cardiac ischemia (rodent, multiple groups) | Full Tβ4 | Reduced infarct size, improved cardiac function, reduced fibrosis |
| Dermal wound healing (rodent) | Full Tβ4 and TB-500 fragment | Accelerated wound closure, improved tensile strength |
| Tendon healing (rodent and equine) | Full Tβ4 and fragment | Improved biomechanical properties of healed tendons |
| Hair growth (rodent) | Full Tβ4 | Stimulated hair follicle stem cell migration and new hair growth |
Potential benefits of TB-500
- Wound and tissue healing — The strongest biological rationale. Cell migration promotion, angiogenesis, and anti-inflammatory signaling all contribute to accelerated repair
- Musculoskeletal recovery — Tendon, ligament, and muscle injuries. The equine track record and rodent data support this application
- Cardiac protection (speculative for non-clinical use) — The Akt-activation pathway and anti-fibrotic properties suggest cardioprotective potential, though this has only been studied in acute MI settings
- Reduced inflammation and fibrosis — TB-500 may help prevent excessive scar formation during healing, promoting functional tissue regeneration over fibrotic scarring
- Hair growth support — Some users report improved hair thickness and density, consistent with the hair follicle stem cell data
- Flexibility and reduced stiffness — Anecdotally reported by many users, possibly related to reduced fibrosis and improved tissue quality in connective tissue
3-min quiz
Tissue repair is a longevity strategy
Healing capacity declines with age. Chia's longevity clinicians evaluate the full spectrum of regenerative approaches and help you build a recovery protocol grounded in evidence.
Dosing protocols discussed in the literature
| Context | Dose | Frequency | Notes |
|---|---|---|---|
| Clinical trial (full Tβ4, cardiac) | 1200 mg IV | Single dose or 3 doses over 7 days | Full-length protein, intravenous, hospital setting |
| Clinical trial (full Tβ4, corneal) | 0.1% eye drops | 2x daily for 28 days | Topical application, ophthalmological setting |
| Community protocol (TB-500 fragment, loading) | 2-2.5 mg | 2x per week for 4-6 weeks | Subcutaneous injection. "Loading phase" for acute injuries |
| Community protocol (TB-500 fragment, maintenance) | 2-2.5 mg | 1x per week or biweekly | Continued support after loading phase |
| Equine dosing (commercial) | 10-20 mg | 1-2x per week | Licensed veterinary use in some jurisdictions for racehorse recovery |
Side effects and risks
- Generally well-tolerated in clinical trials — Full-length Tβ4 showed a favorable safety profile in Phase I/II trials with no serious drug-related adverse events at therapeutic doses
- Injection-site reactions — Redness, pain, or swelling at the subcutaneous injection site. The most commonly reported adverse effect
- Transient fatigue or flu-like symptoms — Some users report mild fatigue in the first few days of use, possibly related to immune modulation
- Head rush or lightheadedness — Occasionally reported, typically transient
- Theoretical cancer concern — Same as BPC-157: TB-500 promotes angiogenesis and cell migration. In theory, this could accelerate growth of existing tumors. No clinical evidence supports this concern, but it cannot be excluded without long-term data
- Potential for existing tumor detection complication — If TB-500 promotes vascularization of a small, quiescent tumor, it could theoretically accelerate its growth or metastatic potential. This is speculative but biologically grounded
- Quality-control risk (2026) — Category 2 status means research-chemical sourcing only. Purity, sterility, and correct peptide identity are not guaranteed
Legal and regulatory status (as of April 2026)
Thymosin beta-4 (and by extension TB-500) was placed on the FDA Category 2 bulk drug substances list in 2023. This classification restricts routine compounding at 503A pharmacies. The molecule has never received FDA approval for any therapeutic indication, despite the clinical trial activity by RegeneRx.
TB-500 is also explicitly banned by WADA under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). It is listed specifically by name as a prohibited substance both in-competition and out-of-competition. Athletes subject to anti-doping testing cannot use TB-500 at any time.
Current availability is limited to research-chemical suppliers. The equine formulation remains commercially available in some jurisdictions for veterinary use, but human-targeted products come exclusively from unregulated sources.
What has Huberman Lab said about TB-500?
Andrew Huberman has discussed TB-500/thymosin beta-4 in the context of healing peptides, typically alongside BPC-157. He has explained the actin-regulation mechanism — noting that TB-500 works through a fundamentally different pathway than BPC-157 (cytoskeletal dynamics vs. NO/growth factor signaling), which provides the rationale for combining them.
Huberman has acknowledged the clinical trial data for full-length Tβ4 as giving it somewhat stronger translational support than BPC-157. He has also noted the distinction between the full protein (used in trials) and the fragment (sold commercially as TB-500), flagging this as an important nuance that most peptide marketing ignores.
In discussions about injury recovery, the podcast has positioned TB-500 as potentially useful for systemic healing support (given its role in cell migration and tissue remodeling throughout the body) versus BPC-157's potentially more localized effects. The regulatory restrictions post-2023 have been acknowledged as limiting legitimate access.
Who might consider TB-500?
- Individuals recovering from significant soft-tissue injuries (muscle tears, tendon/ligament damage) who have failed conventional physical therapy and medical management over extended periods
- People with chronic wounds or impaired healing (though the clinical trial setting for this is diabetic ulcers — a medical context requiring physician oversight)
- Athletes (non-WADA-tested) with cumulative tissue damage seeking systemic repair support alongside rehabilitation protocols
- Those who have tried BPC-157 and want to explore a complementary mechanism (actin dynamics vs. NO/growth factors)
Who should not use TB-500: athletes subject to WADA testing (explicitly banned), anyone with active cancer or concerning lesions (angiogenesis/migration promotion), patients who expect the TB-500 fragment to behave identically to full-length Tβ4 used in clinical trials, or anyone unable to verify product quality and sterility.
Frequently asked questions
No. TB-500 is a synthetic fragment representing the active region (typically amino acids 17-23) of the full 43-amino-acid thymosin beta-4 protein. Clinical trials used full-length Tβ4. The fragment retains key biological activity but may differ in pharmacokinetics, tissue distribution, and duration of effect.
No. Neither TB-500 (the fragment) nor full-length thymosin beta-4 has received FDA approval. Clinical trials for the full protein are ongoing but have not completed Phase III. TB-500 is on the FDA Category 2 restricted compounding list.
They work through different mechanisms (actin/cell migration vs. NO/growth factors) and may be complementary rather than interchangeable. TB-500 has somewhat stronger translational support (Phase II data exists for the parent molecule) while BPC-157 has broader animal data across tissue types. No head-to-head comparison exists. Many users combine both.
Anecdotal reports typically describe initial effects (reduced stiffness, improved mobility) within 1-2 weeks of the loading protocol. Full healing benefits for chronic injuries may take 4-8 weeks. As with all healing peptides, these timelines overlap with natural recovery, making attribution difficult without controlled comparison.
Yes. TB-500/thymosin beta-4 is explicitly listed on the WADA Prohibited List under S2. It is banned both in-competition and out-of-competition. Multiple athletes have received sanctions for TB-500 use.
Animal data shows thymosin beta-4 activates hair follicle stem cell migration and promotes new hair growth in rodent models. Some human users report improved hair thickness. No controlled human trial has been conducted specifically for hair growth. The effect, if real, appears modest — not comparable to finasteride or minoxidil.
Unlike BPC-157 (often injected locally near an injury), TB-500 is typically administered as a standard subcutaneous injection in the abdomen or thigh. Because TB-500's mechanism involves systemic cell migration promotion rather than local concentration-dependent effects, injection site is less critical. The peptide distributes systemically regardless of injection location.
Bottom line
TB-500 benefits from a stronger translational story than most non-approved peptides: its parent molecule (full-length thymosin beta-4) has actual Phase II clinical trial data showing safety and preliminary efficacy signals in cardiac repair and wound healing. The biological mechanism — regulating the most abundant structural protein in your cells — is well-characterized and plausible as a tissue-repair intervention.
The important caveats: the TB-500 fragment is not identical to the full-length protein used in trials; it has not been independently validated in human studies; its long-term safety profile is unknown; and in 2026 it can only be obtained from unregulated sources following the Category 2 classification. The angiogenesis-promotion property that makes it useful for healing also makes it theoretically concerning for anyone with undetected malignancy.
For serious injuries with failed conventional treatment, TB-500 represents one of the more scientifically grounded experimental options — more so than most peptides in the healing category. But "more scientifically grounded than other unproven peptides" is a relative statement, not an endorsement. The proven interventions (physical therapy, PRP, surgical repair, adequate recovery time) remain the clinical standard for good reason.
3-min quiz
Regenerative longevity, clinician-guided
Chia Longevity integrates tissue repair, metabolic optimization, and anti-aging strategies into personalized protocols. Start with understanding your biology.
References
- 1.Goldstein AL, et al. Thymosin beta-4: a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012;12(Suppl 1):S37-S51.
- 2.Bock-Marquette I, et al. Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472.
- 3.Sosne G, et al. Thymosin beta-4 promotes corneal wound healing and modulates inflammatory mediators. Exp Eye Res. 2002;74(2):293-299.
- 4.RegeneRx Biopharmaceuticals. RGN-259 (Thymosin beta-4) Phase II clinical trial results for neurotrophic keratopathy. Company data, 2019.
- 5.Philp D, et al. Thymosin beta-4 increases hair growth by activation of hair follicle stem cells. FASEB J. 2004;18(2):385-387.
- 6.FDA. Bulk Drug Substances — Category 2 list (2023). Includes Thymosin Beta-4.
- 7.WADA. 2026 Prohibited List — S2: Peptide Hormones. TB-500/Thymosin Beta-4 listed.
About this article
Dr. Elena Vasquez — Longevity Medicine, Functional Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
